ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
value factor · long-only model fund

Foundry Healthcare OCFP Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FOCHHYPOTHETICAL MODEL
Since ’99
−65%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Feb 2019
placeholder
Full Sharpe
0.09
Ann. Return (LS)
2.9%
Ann. Volatility
33.4%
Max Drawdown
-88.3%
Test Sharpe ’19–26
-0.17
Test FF5 α (ann.)
-12.5%
vs Fama-French 5
Test FF5 α t-stat
-1.39
not significant
Monthly turnover
12%
of the long leg, per rebalance
Cumulative return (LS)
-65%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.96
what this fund holds
Long leg ann. return
15.9%
buyable, long-only
Long-short Sharpe
0.09
requires shorting
Bottom bucket ann. return
13.0%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1PFE
PFIZER INCHealthcare$142.77B
9.26%
2CVS
CVS HEALTH CORPHealthcare$137.12B
8.89%
3BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
8.04%
4MDT
MEDTRONIC PLCHealthcare$106.50B
6.91%
5HCA
HCA HEALTHCARE INCHealthcare$82.34B
5.34%
6ELV
ELEVANCE HEALTH INCHealthcare$80.92B
5.25%
7CI
CIGNA GROUPHealthcare$74.45B
4.83%
8REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
4.60%
9BSX
BOSTON SCIENTIFIC CORPHealthcare$65.44B
4.24%
10CAH
CARDINAL HEALTH INCHealthcare$53.52B
3.47%
11BDX
BECTON DICKINSON & COHealthcare$43.58B
2.83%
12IQV
IQVIA HOLDINGS INCHealthcare$34.42B
2.23%
13RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
2.17%
14CNC
CENTENE CORPHealthcare$32.81B
2.13%
15ZTS
ZOETIS INCHealthcare$32.10B
2.08%
16BIIB
BIOGEN INCHealthcare$30.41B
1.97%
17GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
1.86%
18DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
1.51%
19LH
LABCORP HOLDINGS INCHealthcare$23.24B
1.51%
20UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
1.47%
21VTRS
VIATRIS INCHealthcare$20.14B
1.31%
22ZBH
ZIMMER BIOMET HOLDINGS INCHealthcare$17.63B
1.14%
23THC
TENET HEALTHCARE CORPHealthcare$16.79B
1.09%
24JAZZ
JAZZ PHARMACEUTICALS PLCHealthcare$15.53B
1.01%
25DVA
DAVITA INCHealthcare$15.21B
0.99%
26EXEL
EXELIXIS INCHealthcare$14.06B
0.91%
27COO
COOPER COMPANIES INCHealthcare$13.99B
0.91%
28BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
0.76%
29BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
0.75%
30EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.72%
31GMED
GLOBUS MEDICAL INCHealthcare$10.45B
0.68%
32HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.60%
33UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.59%
34OSCR
OSCAR HEALTH INCHealthcare$8.77B
0.57%
35ATR
APTARGROUP INCHealthcare$8.46B
0.55%
36PACS
PACS GROUP INCHealthcare$7.30B
0.47%
37RDNT
RADNET INCHealthcare$4.89B
0.32%
38MMSI
MERIT MEDICAL SYSTEMS INCHealthcare$4.41B
0.29%
39WAY
WAYSTAR HOLDING CORPHealthcare$4.27B
0.28%
40CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.26%
41DOCS
DOXIMITY INCHealthcare$3.94B
0.26%
42OGN
ORGANON & COHealthcare$3.55B
0.23%
43HAE
HAEMONETICS CORPHealthcare$3.54B
0.23%
44OPCH
OPTION CARE HEALTH INCHealthcare$3.41B
0.22%
45XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.18%
46TMDX
TRANSMEDICS GROUP INCHealthcare$2.56B
0.17%
47ASTH
ASTRANA HEALTH INCHealthcare$2.50B
0.16%
48PGNY
PROGYNY INCHealthcare$2.50B
0.16%
49PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.15%
50BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.15%
51MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.14%
52ADUS
ADDUS HOMECARE CORPHealthcare$2.14B
0.14%
53AVAH
AVEANNA HEALTHCARE HOLDINGS INCHealthcare$2.11B
0.14%
54SGRY
SURGERY PARTNERS INCHealthcare$2.09B
0.14%
55OMCL
OMNICELL INCHealthcare$2.09B
0.14%
56AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.13%
57HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.13%
58SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.12%
59ANIP
ANI PHARMACEUTICALS INCHealthcare$1.80B
0.12%
60HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.11%
61TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.11%
62FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.11%
63INVA
INNOVIVA INCHealthcare$1.60B
0.10%
64SEPN
SEPTERNA INCHealthcare$1.51B
0.10%
65AHCO
ADAPTHEALTH CORPHealthcare$1.49B
0.10%
66PRGO
PERRIGO CO PLCHealthcare$1.48B
0.10%
67INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.09%
68ARDT
ARDENT HEALTH INCHealthcare$1.46B
0.09%
69AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.09%
70CNMD
CONMED CORPHealthcare$1.30B
0.08%
71COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.08%
72NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.07%
73USPH
U S PHYSICAL THERAPY INCHealthcare$1.12B
0.07%
74CERT
CERTARA INCHealthcare$1.08B
0.07%
75PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.07%
76BVS
BIOVENTUS INCHealthcare$1.01B
0.07%
77TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.06%
78AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.06%
79HSTM
HEALTHSTREAM INCHealthcare$832M
0.05%
80RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.05%
81CSTL
CASTLE BIOSCIENCES INCHealthcare$733M
0.05%
82PHR
PHREESIA INCHealthcare$662M
0.04%
83CRMD
CORMEDIX INCHealthcare$661M
0.04%
84CTEV
CLARITEV CORPHealthcare$518M
0.03%
85OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
0.03%
86VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.03%
87PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.03%
88CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.03%
89EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.03%
90TBRG
TRUBRIDGE INCHealthcare$394M
0.03%
91SLP
SIMULATIONS PLUS INCHealthcare$369M
0.02%
92SPOK
SPOK HOLDINGS INCHealthcare$222M
0.01%
93INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.01%
94OPRX
OPTIMIZERX CORPHealthcare$126M
0.01%
95SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $1.54T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
41%12
33%21
18%5
2%14
1%7
1%5
<1%7
<1%6
<1%5

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 37% toward Growth. +3% unclassified (13 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt98% → Large
SmallLarge
Value ↔ growth tilt37% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.2 (95% CI 0.7-1.6)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
11.8%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.22x
within
parametric
0.99x
within
cornish fisher
0.98x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 24%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2004
Before publication (pre-2004)
-0.01
Sharpe · -0.5% p.a.
January 1999December 2004 · 72 mo
Since publication
0.14
Sharpe · 3.9% p.a.
January 2005July 2026 · 259 mo
Change in Sharpe+0.15the return flipped from negative to positive since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
62%
16 of 26 3-year windows made money
Worst window
-0.42
Sharpe, August 2023 – July 2026
January 1999July 2026
Median Sharpe
0.21
Dispersion
0.45
Best window
1.07

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.49.8%-47.6%
3 yearsp.a.15.8%-18.8%
5 yearsp.a.10.6%-11.4%
10 yearsp.a.11.3%-8.9%
Since inceptionp.a.15.5%-3.7%
Calendar years
YearLong legLong-short
20267 mo15.0%-29.8%
202524.7%-16.0%
20244.1%0.1%
2023-2.3%-30.4%
20226.5%14.5%
202124.7%42.3%
202010.6%-12.7%
201918.1%-21.3%
20186.0%20.3%
201716.5%-15.3%
2016-2.9%3.1%
20157.7%-7.2%
201425.0%-24.4%
201350.9%-2.7%
201219.8%-12.5%
201124.3%41.3%
201019.1%2.7%
200936.7%12.2%
2008-16.6%35.8%
20072.4%17.1%
200620.8%14.4%
200510.5%18.8%
20048.2%-1.9%
200339.0%-15.9%
20022.3%39.7%
200118.0%12.6%
200077.5%-60.5%
1999-2.0%-32.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FOCH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-02-10 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$1.54T

Methodology

The Foundry Healthcare OCFP Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a OCFP signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.